Aarti Pharmalabs Limited (AARTIPHARM) — Announcement | 7 August 2026

· NSE Neutral
By StockFin Research Team AI-Assisted Analysis Source: BSE/NSE Filings
📢 Key Event
Board approves Q1 results, ₹149 crore capex, and leadership role changes effective October 1, 2026
🔄 What Changed
Net profit increased from ₹6,203.07 lakhs to ₹7,130.66 lakhs (standalone) and from ₹6,112.41 lakhs to ₹7,614.27 lakhs (consolidated); capex of ₹149 crores approved; leadership roles changed pending AGM approval
🔮 What's Next
None
💡 Investor Takeaway
The company is expanding capacity and reshuffling leadership ahead of the AGM, signaling growth focus and governance updates for shareholders.

Aarti Pharmalabs announced its unaudited standalone and consolidated financial results for Q1 June 2026, showing revenue of ₹53,751.91 lakhs (standalone) and ₹53,624.96 lakhs (consolidated), with net profit of ₹7,130.66 lakhs and ₹7,614.27 lakhs respectively. The board approved capacity expansion with ₹149 crores capex and changed leadership roles for Rashesh Gogri and Hetal Gogri Gala effective October 1, 2026, pending shareholder approval at the AGM. The filing includes regulatory disclosures under SEBI LODR and auditor review reports.

📄 View Original Announcement (PDF)

About Aarti Pharmalabs Limited (AARTIPHARM)

Healthcare · Pharmaceuticals · Listed on NSE

Market Cap: ₹7,657.91 Cr P/E: 35.9 ROE: 10.7% ROCE: 14.1% Div Yield: 0.41%

View full AARTIPHARM stock details →

📡 Get AI alerts when AARTIPHARM files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track AARTIPHARM — Free

📊 More AARTIPHARM filings

See all AARTIPHARM filings →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when AARTIPHARM files new disclosures

Track AARTIPHARM filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track AARTIPHARM — Free

Free account · 2 AI queries/day